Publication
The clinical landscape of HIF2α inhibitors in oncology
State-of-the-art review of HIF2α inhibition, highlighting the biological discoveries, structural breakthroughs, and clinical advances that established HIF2α inhibitors as a therapeutic strategy in kidney cancer and other hypoxia-driven malignancies.
Citation
Saad E†, Machaalani M†, McDermott DF, Choueiri TK. The clinical landscape of HIF2α inhibitors in oncology. Nature Reviews Clinical Oncology. 2026. doi: 10.1038/s41571-026-01145-y. †Equal contribution.